BioSpace News Archive

Job Trends

The BioMidwest Region Features Lifestyle Bonuses and Cutting-Edge Science

Why not take advantage of the perks of a lower cost of living, slower pace, and opportunities to make a big impact in some important disease areas?

July 26, 2021
·
4 min read
·
Heather McKenzie
Business

PerkinElmer Continues Rapid Life Science Growth with Massive $5.25B Acquisition

It’s been a long season of acquisitions for PerkinElmer. Now in its largest purchase ever, the Massachusetts-based company is dropping a massive $5.25 billion in cash and stock to buy biomedical research tool company BioLegend.

July 26, 2021
·
2 min read
·
Kate Goodwin
FDA

Following FDA Scolding, CytoDyn Investor Groups Seek New Direction

In a filing with the U.S. Securities and Exchange Commission earlier this month, Rosenbaum and his investment group nominated five directors to elect the CytoDyn board.

July 26, 2021
·
2 min read
·
Alex Keown
Drug Development

Allergan Eye Drops for Presbyopia Hits All Endpoints, Focuses In on Approval

The company said its Allergan eye drops met both its primary and key secondary endpoints, with patients reporting near and intermediate improvements in vision.

July 26, 2021
·
3 min read
·
Vanessa Doctor, RN
Drug Development

Abeona’s Gene Therapy for Rare Sanfilippo Syndrome Shines in Early Trials

Abeona Therapeutics’ shares popped 18.32% in pre-market trading after New York and Cleveland-based company announced magnetic resonance imaging (MRI) data from its Phase I/II Transpher A trial in San Filippo Syndrome Type A (MPS IIIA).

July 26, 2021
·
3 min read
·
Mark Terry
Business

Lantern, Allarity Come Together to Tackle Bladder, Prostate Cancer

Lantern will reacquire the Irofulven program and evaluate its potential for advanced development to treat bladder and prostate cancers.

July 26, 2021
·
2 min read
·
Vanessa Doctor, RN
Policy

Cross-Contamination of Medications is Wider Issue than Realized: Report

A recent report suggests that cross-contamination is not all that uncommon of an issue, and maybe inevitable.

July 26, 2021
·
2 min read
·
Alex Keown
Drug Development

FDA Rejects Incyte’s PD-1 For Anal Cancer, Requires More Proof of Benefit

The FDA’s ODAC met to discuss retifanlimab and voted 13-4 that a regulatory decision for the drug for this indication should be deferred until more data was available.

July 26, 2021
·
2 min read
·
Mark Terry
Drug Development

Iterum Therapeutics Plunges Following FDA Rejection of Oral Sulopenem

The FDA called for Iterum to conduct an additional clinical study that uses a different drug for comparison and to determine optimal dosing.

July 26, 2021
·
2 min read
·
Alex Keown
Urinary Catheters Market: Increasing Prevalence of Urinary Incontinence to Drive Urinary Catheters Market Growth

The urinary catheters market was valued at US$ 2,526.8 million in 2017 and it is projected to reach US$ 4,811.0 million in 2025; it is expected to grow at a CAGR of 8.6% from 2017 to 2025.

July 26, 2021
·
4 min read